by In2Pharma | Feb 10, 2024 | News
The Netherlands Via the MEB website, a planning tool is already available to reserve a timeslot for requesting assessment procedures for decentralized procedures. The planning tool helps the MEB to properly plan the required capacity. This tool has now been expanded...
by In2Pharma | Jan 11, 2023 | News
The Netherlands Marketing authorization holders who want to temporarily supply a medicine in a different packaging in the event of a medicine shortage will need permission from the MEB from 1 January 2023. The MEB will take over this task from the Healthcare and Youth...
by In2Pharma | Jun 21, 2022 | News
The Netherlands On March 30, 2022, the Dutch Health Authorities (MEB) updated the local policy regarding aRMM which is applicable for new and updated materials. No changes are required for aRMM that are already approved by MEB nor for ongoing procedures. The most...
by In2Pharma | Jun 22, 2021 | News
The Netherlands The Medicines Evaluation Board (MEB) has amended its policy regarding the national implementation of ‘additional Risk Minimization Measures’ (aRMM) (MEB 45). This is still a draft version. The main changes are: 1. Clarification of the...
by In2Pharma | Jun 11, 2021 | News
The Netherlands The Medicines Evaluation Board (MEB) has amended its policy regarding the labeling of medicines for humans (MEB 6). The MEB recognizes the value that pictograms on the packaging can have to clarify the information. Pictograms on the packaging of...
